Showing results (911-920 of 4,514) with videos related to

Sort By:
Pageof 452
Future Oncology (London, England)|March 13, 2023
A multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE)Sharmeen Mahmood, Daneng Li, Arielle Lee, et al.
Future Oncology (London, England)|March 9, 2023
Immune-induced pneumonia in patients with advanced solid tumors treated with immunotherapy: a real-world assessmentChuhan Wang, Hong Zhu, Haiwen Huang, et al.
Future Oncology (London, England)|March 6, 2023
Preferences for first-line treatment of advanced urothelial carcinoma among US practicing oncologists and patientsPetros Grivas, Phani Veeranki, Kevin Chiu, et al.
Future Oncology (London, England)|March 6, 2023
TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumorsMisako Nagasaka, Yuichiro Ohe, Caicun Zhou, et al.
Future Oncology (London, England)|March 13, 2023
Characteristics and outcomes of elderly patients with acute myeloid leukemia who receive no treatment in the Surveillance, Epidemiology and End Results-Medicare databaseCharles Dharmani, Eric Wang, Nora Tu, et al.
Future Oncology (London, England)|November 15, 2022
Physician- and patient-reported symptom concordance and association with quality of life in hepatocellular carcinomaAndrea Leith, Urpo Kiiskinen, Allicia C Girvan, et al.
Future Oncology (London, England)|November 16, 2022
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancerSara A Hurvitz, Thomas Bachelot, Giampaolo Bianchini, et al.
Future Oncology (London, England)|November 18, 2022
Atezolizumab plus tivozanib for immunologically cold tumor types: the IMMCO-1 trialBrian H Ramnaraign, Ji-Hyun Lee, Azka Ali, et al.
Future Oncology (London, England)|November 18, 2022
Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinomaTiago Biachi de Castria, Danny N Khalil, James J Harding, et al.
Future Oncology (London, England)|November 19, 2025
Trends in initial primary treatment approach and biomarker testing across social determinants of health in early-stage non-small cell lung cancerXiaohan Hu, Yu-Han Kao, Ashwini Arunachalam, et al.
Pageof 452